Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022:1366:123-135.
doi: 10.1007/978-981-16-8702-0_8.

Influenza Virus Entry inhibitors

Jie Yang  1 , Shuwen Liu  2
Affiliations
Review

Influenza Virus Entry inhibitors

Jie Yang et al. Adv Exp Med Biol. 2022.

Abstract

Influenza is a major challenge to health and the global economy. However, the increasing emergence of drug resistance during influenza pandemics cannot be ignored. It is particularly important to design and develop anti-influenza drugs with novel mechanisms of action for the treatment and prevention of influenza virus infections. Virus entry is the first essential step in the viral life cycle, the prevention of which leads to suppression of viral infectivity and is an attractive antiviral strategy. Here, we review the development of influenza entry inhibitors and their performance in clinical trials, including small molecule, natural product, peptide-based entry inhibitors, and other types of entry inhibitors, herein discussing some open questions. Assay methods of influenza virus entry inhibitors are also outlined.

Keywords: Entry inhibitors; Hemagglutinin; Influenza virus; Therapeutics; Virus entry.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

References

    1. Antanasijevic A, Cheng H, Wardrop DJ, Rong L, Caffrey M (2013) Inhibition of influenza H7 hemagglutinin-mediated entry. PLoS One 8(10):e76363. https://doi.org/10.1371/journal.pone.0076363 - DOI - PubMed - PMC
    1. Baranovich T, Saito R, Suzuki Y, Zaraket H, Dapat C, Caperig-Dapat I, Oguma T, Shabana II, Saito T, Suzuki H (2010) Emergence of H274Y oseltamivir-resistant A(H1N1) influenza viruses in Japan during the 2008-2009 season. J Clin Virol 47(1):23–28. https://doi.org/10.1016/j.jcv.2009.11.003 - DOI - PubMed
    1. Barnard KN, Alford-Lawrence BK, Buchholz DW, Wasik BR, LaClair JR, Yu H, Honce R, Ruhl S, Pajic P, Daugherity EK, Chen X, Schultz-Cherry SL, Aguilar HC, Varki A, Parrish CR (2020) Modified sialic acids on mucus and erythrocytes inhibit influenza A virus hemagglutinin and neuraminidase functions. J Virol 94(9):e01567. https://doi.org/10.1128/jvi.01567-19 - DOI - PubMed - PMC
    1. Basu A, Komazin-Meredith G, McCarthy C, Antanasijevic A, Cardinale SC, Mishra RK, Barnard DL, Caffrey M, Rong L, Bowlin TL (2017) Molecular mechanism underlying the action of influenza A virus fusion inhibitor MBX2546. ACS Infect Dis 3(5):330–335. https://doi.org/10.1021/acsinfecdis.6b00194 - DOI - PubMed - PMC
    1. Belser JA, Lu X, Szretter KJ, Jin X, Aschenbrenner LM, Lee A, Hawley S, Kim DH, Malakhov MP, Yu M, Fang F, Katz JM (2007) DAS181, a novel sialidase fusion protein, protects mice from lethal avian influenza H5N1 virus infection. J Infect Dis 196(10):1493–1499. https://doi.org/10.1086/522609 - DOI - PubMed

Substances

LinkOut - more resources